Efficacy of Trametinib in Neurofibromatosis Type 1–Associated Gastrointestinal Stromal Tumors: A Case Report
Trametinib, an MEK inhibitor, may offer a new therapeutic option for patients with NF1-related GIST.
Authors
- Toru Mukohara (ORCID: https://orcid.org/0000-0002-8573-418X)
- Misao Fukuda (ORCID: https://orcid.org/0009-0000-7720-3875)
- Takeshi Kuwata (ORCID: https://orcid.org/0000-0003-0044-953X)
- Yoichi Naito (ORCID: https://orcid.org/0000-0002-8490-9064)
- Kuniko Sunami (ORCID: https://orcid.org/0000-0002-7137-5649)
Institutions
- National Cancer Center Hospital East (JP)
- Tokyo National Hospital (JP)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1200/po.23.00649
- Citations
- 6
- Primary Topic
- Neurofibromatosis and Schwannoma Cases
- Type
- article
- Field-Weighted Citation Impact
- 2.21